ArticleCureus2025
Contrast-Enhanced Mammography Versus Digital Mammography and Tomosynthesis in Dense Breasts: Diagnostic Accuracy and Impact on Surgical Planning in Multifocal and Multicentric Breast Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDense breast tissue poses a major diagnostic challenge in breast cancer detection, as it can obscure lesions on digital mammography (DM) and limit the sensitivity of digital breast tomosynthesis (DBT). Contrast-enhanced mammography (CEM) combines morphological and functional assessment, potentially improving detection accuracy and influencing surgical decision-making. PURPOSE: To compare the diagnostic performance of CEM, DM, and DBT in detecting multifocal and multicentric breast cancer in women with dense breasts, using histopathology as the reference standard, and to evaluate the impact of CEM findings on surgical management. MATERIALS AND
methodsThis prospective comparative study included 185 women with Breast Imaging Reporting and Data System (BI-RADS) density categories C or D who underwent DM, DBT, and CEM prior to biopsy or surgery between April and June 2025. Two experienced breast radiologists independently evaluated lesion detection, conspicuity, diagnostic confidence, and lesion size. Statistical analyses included McNemar's test, Wilcoxon signed-rank test, Bland-Altman analysis, Pearson correlation, intraclass correlation coefficient (ICC), and logistic regression to assess predictors of surgical change.
resultsCEM detected the index lesion in 96.8% of cases, outperforming DBT (69.2%) and DM (51.9%) (p < 0.001). Lesion conspicuity and radiologist confidence were highest with CEM (p < 0.001). CEM identified ≥2 additional malignant lesions in 43.7% of patients, closely matching histopathology (43.2%), and altered surgical management in 36.8% of cases--prompting wider excision (16.8%) or mastectomy (16.2%). Lesion size correlation with histopathology was strongest for CEM (r = 0.969-0.987; ICC > 0.87). Logistic regression revealed that additional CEM-detected lesions were the strongest independent predictor of surgical modification (OR ≈ 71.7, p < 0.001). Bland-Altman plots confirmed excellent agreement with minor overestimation (mean bias ≈ +5 mm).
conclusionCEM demonstrated superior diagnostic performance over DM and DBT in women with dense breasts, offering enhanced lesion conspicuity, greater radiologist confidence, and high concordance with histopathology. Its significant impact on surgical planning highlights CEM as a cost-effective, accessible alternative to MRI for preoperative assessment in dense-breast populations, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.